HomeMEDTRONIC plcMedtronic Statement Regarding New York Times Article on March 29, 2020

Medtronic Statement Regarding New York Times Article on March 29, 2020

Medtronic plc (NYSE:MDT) issued the following statement regarding a New York Times article mentioning Medtronic on March 29, 2020:

Medtronic seeks to provide additional facts regarding the New York Times article entitled The U.S. Tried to Build a New Fleet of Ventilators. The Mission Failed.”, dated March 29, 2020. The article lacks important information regarding Newport Medical’s contract with the U.S. Government.

Medtronic, who had no relationship with Newport Medical and who did not purchase Covidien until 2015 – nearly three years after the contract dissolved – had no prior knowledge of or involvement in this contract in any manner.

Since the outset of COVID-19 in early 2020 in China, Medtronic has ramped up production of its high-performance ventilators by more than 40 percent. The company’s employees are working 24/7 across multiple shifts to produce as many high-performance ventilators as possible – from a production level of approximately 100 PB980 ventilators pre-pandemic to more than 225 vents per week to date with plans to double that again to more than 500 vents per week. In addition, the company is working with third parties to explore other non-traditional mechanisms to increase production of ventilators, including providing its intellectual property and ventilator designs to the public for third-party ventilator production.

Medtronic’s review and understanding of the facts regarding Newport Medical are as follows:

  • In September 2010, Newport Medical, an independent, approximately 100-person company based in California, entered into a contract with the Government to develop a new fully featured, mid-level ventilator at a cost of $3,000.00. The contract required that the ventilator be capable of use in neonatal through adult populations. The three-year contract was initiated on September 24, 2010 with an expected completion date of September 23, 2013.
  • In May 2012, Newport Medical was then acquired by Covidien in order to provide Covidien with access to Newport’s existing mid-level acuity ventilators, thus expanding Covidien’s portfolio of ventilators into the mid-level acuity category.
  • Through the due diligence process, Covidien became aware of Newport Medical’s contract with the Government. Covidien learned that Newport’s work on the ventilator design for the Government had significant gaps between what it had promised the Government and what it could deliver – both in terms of being able to achieve the cost of production specified in the contract and product features and performance. Covidien management questioned whether Newport’s ability to complete the project as agreed to in the contract was realistic.
  • Covidien management attempted through 2013 to address and fill the gaps in Newport’s capabilities, however, they were unable to do so. They were not able to deliver a product close to the target cost of manufacture required by the contract specifications. In addition, the company was unable to secure FDA approval for use in neonatal populations – a contract requirement.
  • In November 2013, Newport/Covidien and the Government mutually agreed to end the contract. The Government retained ownership of all equipment, tooling, and intellectual property rights in the event the Government were to pursue the project with another manufacturer. To our knowledge, no one has provided such a ventilator to the Government to date.
  • Bob White, Medtronic’s EVP and President of its Minimally Invasive Therapies Group, was made available to the New York Times to discuss ventilators and the current efforts by Medtronic to supply the marketplace in light of COVID-19. In the process of the interview, he was asked about this contract. Mr. White did not immediately recall the specific details of the contract – events that occurred nearly eight years ago.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy